title: Epilepsy in childhood: an audit of clinical practice.
abstract: BACKGROUND
  It is not known how many children with epilepsy may not need treatment with antiepileptic drugs (AEDs), how many respond unsatisfactorily to subsequent treatment regimens, and how many achieve "acceptable control" despite lack of remission.
  
  
  METHODS
  In a prospective multicenter hospital-based study, 494 children with a broad range of seizure types and types of epilepsy were followed up for at least 2 years. There was no standard treatment protocol. We describe the treatment strategies applied to these children by the neurologists in charge and outcome with respect to remission from seizures.
  
  
  RESULTS
  Treatment was initially withheld in 29% of the children, and after 2 years 17% still had not received any AEDs. There were no serious complications caused by withholding treatment. Of the children treated with AEDs, 60% were still using the first AED after 2 years; 80% received monotherapy and 20%, polytherapy. Children with severe symptomatic epilepsies, such as the West or Lennox-Gastaut syndrome, received polytherapy early on in the course of treatment. When 3 regimens had failed, the chance of achieving a remission of more than 1 year with subsequent regimens was 10%. Nevertheless, 15 of 50 children receiving AEDs in whom the "longest remission ever" was less than 6 months did achieve acceptable seizure control according to the neurologist in charge of treatment. Hence, of 494 children, only 35 (7%) developed an intractable form of epilepsy, defined as failure to bring seizures under acceptable control.
  
  
  CONCLUSIONS
  A substantial percentage of children with new-onset epilepsy did not need treatment with AEDs. Chances of achieving a good outcome declined with subsequent treatment regimens. Not all children with recurrent seizures were suffering from intractable epilepsy; some had achieved acceptable control of seizures.
authors.affiliation: Department of Child Neurology, Westeinde Hospital, The Hague, The Netherlands.
authors.forename: H A
authors.initials: HA
authors.lastname: Carpay
authors.forename: W F
authors.initials: WF
authors.lastname: Arts
authors.forename: A T
authors.initials: AT
authors.lastname: Geerts
authors.forename: H
authors.initials: H
authors.lastname: Stroink
authors.forename: O F
authors.initials: OF
authors.lastname: Brouwer
authors.forename: A C
authors.initials: AC
authors.lastname: Boudewyn Peters
authors.forename: C A
authors.initials: CA
authors.lastname: van Donselaar
mesh_terms: D000293:Adolescent; D000927:Anticonvulsants / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004359:Drug Therapy, Combination; D004827:Epilepsy / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006761:Hospitals; D006801:Humans; D007223:Infant; D008297:Male; D008485:Medical Audit; D009426:Netherlands; D011379:Prognosis; D011446:Prospective Studies; D019233:Retreatment; D016896:Treatment Outcome
chemical_list: D000927:Anticonvulsants